Holen Sie sich die Stockscreener-App
15.53
8.38%
-1.41
Handel nachbörslich:
15.53
Schlusskurs vom Vortag:
$16.94
Offen:
$16.83
24-Stunden-Volumen:
2.98M
Relative Volume:
0.90
Marktkapitalisierung:
$971.08M
Einnahmen:
$16.10M
Nettoeinkommen (Verlust:
$-198.97M
KGV:
-4.4615
EPS:
-3.4809
Netto-Cashflow:
$-183.99M
1W Leistung:
+8.76%
1M Leistung:
-24.29%
6M Leistung:
-5.85%
1J Leistung:
+12.63%
1-Tages-Spanne:
$15.04
$17.29
1-Wochen-Bereich:
$15.04
$19.22
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.53 | 1.06B | 16.10M | -198.97M | -183.99M | -3.4809 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline – Company AnnouncementFT.com - Financial Times
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class ... - Bluefield Daily Telegraph
uniQure (QURE) Upgraded to Outperform by Mizuho, Price Target Ra - GuruFocus
uniQure upgraded at Mizuho on improved outlook for Huntington's asset AMT-130 - Seeking Alpha
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class ActionHagens Berman - PR Newswire
A Unique Situation For UniQure (QURE) - Seeking Alpha
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
HC Wainwright Has Negative Forecast for uniQure Q1 Earnings - MarketBeat
Atika Capital Management LLC Invests $5.25 Million in uniQure N.V. $QURE - MarketBeat
Lawsuit filed for Investors who lost money with shares of uniQure N.V. (NASDAQ: QURE) - openPR.com
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP - NewMediaWire
QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 – Company AnnouncementFT.com - Financial Times
QURE LAWSUIT ALERT: Levi & Korsinsky Notifies uniQure N.V. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
uniQure (QURE) Gains Momentum with Mizuho's Rating Upgrade and Price Target Raise | QURE Stock News - GuruFocus
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. - GlobeNewswire
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In Focus - Sahm
Why Is uniQure Stock Skyrocketing Monday? - Sahm
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $31 to $70 - 富途牛牛
uniQure N.V. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your RightsQURE - Morningstar
uniQure's (QURE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? - Benzinga
uniQure (QURE) Shares Set for Growth Amid Regulatory Changes - GuruFocus
Jefferies Financial Group Inc. Reduces Holdings in uniQure N.V. $QURE - MarketBeat
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
UNIQURE N.V. (QURE) DEADLINE ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - ACCESS Newswire
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
UniQure N.V. (QURE): RBC Capital Upgrades Rating to Outperform With Significant Upside Potential - 富途牛牛
Forecast brighter for Uniqure with Prasad’s departure? - BioWorld MedTech
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
uniQure (QURE) Stock Soars 36% as FDA’s Vinay Prasad Plans April Exit - MEXC
QURE INVESTOR ALERT: uniQure Faces Securities Class Action - GlobeNewswire
QURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to - The National Law Review
QURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 13, 2026 - NewMediaWire
Levi & Korsinsky Notifies Shareholders of uniQure N.V.(QURE) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire Inc.
QURE Gains Momentum with Chardan Capital's Increased Price Target | QURE Stock News - GuruFocus
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
What the Options Market Tells Us About uniQure - Benzinga
UniQure (QURE) Shares Surge Following FDA Official's Departure - GuruFocus
Dragomir News: UniQure’s Price Volatility Amidst FDA Comments and Dr. Prasad’s Departure - timothysykes.com
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - Yahoo Finance
uniQure (NASDAQ:QURE) Shares Gap Up After Analyst Upgrade - MarketBeat
Wells Fargo Upgrades uniQure (QURE) with Significant Price Targe - GuruFocus
QURE: RBC Capital Upgrades uniQure with a Significant Price Targ - GuruFocus
Is the FDA sabotaging medical companies? UniQure’s valuation rollercoaster - XTB.com
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '26 |
Sale |
9.06 |
808 |
7,320 |
189,669 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '26 |
Sale |
9.06 |
3,412 |
30,913 |
138,483 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '26 |
Sale |
9.06 |
12,000 |
108,720 |
226,581 |
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):